Role of Fibric Acid Derivatives in the Management of Risk Factors for Coronary Heart Disease

This publication has 104 references indexed in Scilit:

• Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
  New England Journal of Medicine, 1998
• Expression of Peroxisome Proliferator-Activated Receptor γ (PPARγ) in Rat Aortic Smooth Muscle Cells
  Biochemical and Biophysical Research Communications, 1998
• Expression of Peroxisome Proliferator-Activated Receptor α (PPARα) in Primary Cultures of Human Vascular Endothelial Cells
  Biochemical and Biophysical Research Communications, 1998
• Associations of HDL ₂ and HDL ₃ Subfractions With Ischemic Heart Disease in Men
  Arteriosclerosis, Thrombosis, and Vascular Biology, 1997
• Effect of a Combination of Gemfibrozil and Niacin on Lipid Levels
  The Journal of Clinical Pharmacology, 1996
• Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor.
  Journal of Clinical Investigation, 1995
• Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia.
  Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1993
• Blood pressure and high blood pressure. Aspects of risk.
  Hypertension, 1991
• Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
  New England Journal of Medicine, 1987
• HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study.
  Circulation, 1977